Melinta Therapeutics (Melinta Therapeutics) 6-1 Month Momentum % : -98.13% (As of Apr. 26, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Melinta Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-26), Melinta Therapeutics's 6-1 Month Momentum % is -98.13%.

The industry rank for Melinta Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

MLNTQ's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: 4.08 vs MLNTQ: -98.13

Competitive Comparison of Melinta Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Melinta Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melinta Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Melinta Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Melinta Therapeutics's 6-1 Month Momentum % falls into.

Melinta Therapeutics (OTCPK:MLNTQ) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Melinta Therapeutics (OTCPK:MLNTQ) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Melinta Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Melinta Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Melinta Therapeutics (Melinta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Melinta Therapeutics Inc (OTCPK:MLNTQ) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Whippany Road, Morristown, NJ, USA, 07963

Website

http://www.melinta.com

Melinta Therapeutics Inc is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications.

Executives

John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Thomas P Koestler	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Zaccardelli	director	300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Bruce Downey	director
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Daniel Mark Wechsler	director, officer: See Remarks	2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
John Temperato	officer: Chief Commercial Officer	C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Goldstein Dov A Md	director
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
P Sherrill Neff	director	C/O RESOURCE AMERICA, INC., 1845 WALNUT STREET, 18TH FLOOR, PHILADELPHIA PA 19103
Prabhavathi Fernandes	director, officer: President and CEO	114 MILTON AVENUE, CHAPEL HILL NC 27514
Intersouth Partners Vii L P	10 percent owner	406 BLACKWELL SUITE 200, DURHAM NC 27701
Intersouth Associates Vii, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701
Intersouth Associates Vi, Llc	10 percent owner	406 BLACKWELL STREET, SUITE 200, DURHAM NC 27701